PDCD1 and hepatocellular carcinoma: demonstrated complete pathological remission following surgical resection in a HCC patient who underwent an 8-month course of sintilimab (PD-1 inhibitor) combined with oral lenvatinib (March to November 2023), supplemented by one session of transarterial therapy.